menu
    • menu
    [{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"Aspen Pharmacare Holdings \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Pharmacare Holdings \/ Mylan"}]

    Find Clinical Drug Pipeline Developments & Deals for Fondaparinux Sodium

    Menu

    Fondaparinux Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen Pharmacare Holdings

                            South Africa
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Viatris

                            Deal Size : $757.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

                            Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

                            Brand Name : Arixtra

                            Molecule Type : Small molecule

                            Upfront Cash : $310.4 million

                            September 08, 2020

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Viatris

                            Deal Size : $757.2 million

                            Deal Type : Acquisition

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth